Scott CR. The genetic tyrosinemias. Am J Med Genet C Semin Med Genet. 2006;142C(2):121-126.
[2]
Sniderman King L, Trahms C, Scott CR. Tyrosinemia Type I. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle (WA): University of Washington; 1993-2024.
[3]
Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. Are there any consequences of the accumulation of p-hydroxyphenylpyruvate in tyrosinemia type II? J Inherit Metab Dis. 2008;31(3):410-417.
[4]
Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347(26):2111-2121.
[5]
van Spronsen FJ, van Rijn M, Meyer U, et al. Dietary considerations in tyrosinemia type I. J Inherit Metab Dis. 1996;19(3):392-395.
[6]
Holme E, Lindstedt S. Diagnosis and treatment of tyrosinemia type I. J Inherit Metab Dis. 1998;21(5):507-517.
[7]
Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: A US and Canadian consensus group review and recommendations. Genet Med. 2017;19(12).
[8]
Roth KS. Tyrosinemia. Medscape Reference. Updated 2023.
[9]
de Laet C, Dionisi-Vici C, Leonard JV, et al. Clinical recommendations for the management of hepatic tyrosinemia type I. Orphanet J Rare Dis. 2013;8:5.
[10]
Morrow G, Tanguay RM. Biochemical and clinical aspects of hereditary tyrosinemia type 1. Adv Exp Med Biol. 2017;959:9-24.